此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

疫苗接种前和接种时口服铁补充剂对缺铁肯尼亚女性免疫反应的影响 (DIVA_II)

2026年11月16日 更新者:Swiss Federal Institute of Technology

Iron deficiency (ID) anemia (IDA) is a global public health problem, with the highest prevalence in Africa. Vaccines often underperform in low- and middle-income countries (LMIC), and undernutrition, including ID, likely plays a role. Recent studies have shown the importance of iron status in vaccine response. Intravenous iron given at time of vaccination improved response to yellow fever and COVID-19 vaccines in IDA Kenyan women. Whether oral iron treatment would have a similar beneficial effect on vaccine response is uncertain. Also, timing of oral iron treatment needs further investigation.

The co-primary objectives of this study are to assess 1) whether IDA in Kenyan women impairs vaccine response, and whether oral iron treatment improves their response; 2) the timing of oral iron treatment to improve vaccine response (prior to vaccination vs at time of vaccination).

We will conduct a double-blind randomized controlled trial in southern Kenya to assess the effects of iron supplementation on response to three single-shot vaccines: Johnson & Johnson COVID- 19 (JJ COVID-19), the quadrivalent meningococcal vaccine (MenACWY) and the typhoid Vi polysaccharide vaccine (Typhim Vi). Women with IDA will be recruited and randomly assigned to three study groups: group 1 (pre- treatment) will receive 100 mg oral iron as ferrous sulfate (FeSO4) daily on days 1-56; group 2 (simultaneous treatment) will receive matching placebo daily on days 1-28, and 100 mg oral iron as FeSO4 daily on days 29-56; and group 3 (control) will receive matching placebo daily on days 1-56. Women in all groups will receive the JJ COVID-19 vaccine, the MenACWY and the Typhim Vi vaccine on day 28. Cellular immune response and serology will be measured at 28 days after vaccination in all groups.

研究概览

研究类型

介入性

注册 (实际的)

215

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Kenya
      • Nairobi、Kenya、肯尼亚、00200
        • Jomo Kenyatta University Of Agriculture And Technology

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 49年 (成人)

接受健康志愿者

是的

有资格学习的性别

女性

描述

Inclusion Criteria:

  • Willing and able to give informed consent for participation in the trial
  • Female aged 18-49 years
  • Moderate anemia (Hb <110 g/L, but not severely anemic with Hb <80 g/L)
  • Iron deficient (ZnPP >40 mmol/mol haem)
  • Anticipated residence in the study area for the study duration

Exclusion Criteria:

  • Major chronic infecious disease (e.g., HIV infection);
  • Major chronic non-infecious disease (e.g., Type 2 diabetes, cancer);
  • Chronic medications;
  • Use of iron-containing mineral and vitamin supplementation 2 weeks prior to study start;
  • COVID-19 vaccine or confirmed COVID-19 infection within the past 2 years
  • MenACWY vaccine in the past
  • Typhim Vi vaccine in the past
  • Pregnant (confirmed by rapid test during screening)
  • Malaria (confirmed by rapid test) à study start will be postponed

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:其他
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
实验性的:Pre-treatment group

Participants assigned to this group will receive 100 mg oral iron daily on study days 1-56.

Iron supplements as 100 mg oral iron as FeSO4 given daily

MenACWY vaccination given on day 28 to all participants

Johnson & Johnson COVID- 19 (JJ COVID-19) vaccination given on day 28 to all participants

Typhim Vi vaccination given on day 28 to all participants

实验性的:Simultaneous treatment group

Participants assigned to this group will receive placebo daily on study days 1-28 and 100 mg oral iron daily on study days 29-56.

Iron supplements as 100 mg oral iron as FeSO4 given daily

MenACWY vaccination given on day 28 to all participants

Johnson & Johnson COVID- 19 (JJ COVID-19) vaccination given on day 28 to all participants

Typhim Vi vaccination given on day 28 to all participants

matching placebo capsules given daily

安慰剂比较:Control group

Participants assigned to this group will receive placebo daily on study days 1-56.

Iron supplements as 100 mg oral iron as FeSO4 given daily

MenACWY vaccination given on day 28 to all participants

Johnson & Johnson COVID- 19 (JJ COVID-19) vaccination given on day 28 to all participants

Typhim Vi vaccination given on day 28 to all participants

matching placebo capsules given daily

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
JJ COVID-19 vaccine response
大体时间:Day 56

Anti-spike (S1) IgG and anti-receptor-binding domain (RBD) IgG against SARS-COV-2

Day 56
MenACWY vaccine response
大体时间:Day 56

Measurement of antibody response against serogroups A, C, W, and Y.

Day 56
Typhoid vaccine response
大体时间:Day 56

Measurement of antibody response against Typhoid

Day 56

次要结果测量

结果测量
措施说明
大体时间
Hemoglobin
大体时间:Day 1

iron status

Day 1
Hemoglobin
大体时间:Day 28

iron status

Day 28
Hemoglobin
大体时间:Day 56

iron status

Day 56
Serum ferritin
大体时间:Day 1

iron status

Day 1
Serum ferritin
大体时间:Day 28

iron status

Day 28
Serum ferritin
大体时间:Day 56

iron status

Day 56
soluble transferrin receptor
大体时间:Day 1

iron status

Day 1
soluble transferrin receptor
大体时间:Day 28

iron status

Day 28
soluble transferrin receptor
大体时间:Day 56

iron status

Day 56
Plasma iron
大体时间:Day 1

iron status

Day 1
Plasma iron
大体时间:Day 28

iron status

Day 28
Plasma iron
大体时间:Day 56

iron status

Day 56
Total iron binding capacity
大体时间:Day 1

iron status

Day 1
Total iron binding capacity
大体时间:Day 28

iron status

Day 28
Total iron binding capacity
大体时间:Day 56

iron status

Day 56
Transferrin saturation
大体时间:Day 1

iron status

Day 1
Transferrin saturation
大体时间:Day 28

iron status

Day 28
Transferrin saturation
大体时间:Day 56

iron status

Day 56
C- reactive protein
大体时间:Day 1

inflammation status

Day 1
C- reactive protein
大体时间:Day 28

inflammation status

Day 28
C- reactive protein
大体时间:Day 56

inflammation status

Day 56
alpha- 1- glycoprotein
大体时间:Day 1

inflammation status

Day 1
alpha- 1- glycoprotein
大体时间:Day 28

inflammation status

Day 28
alpha- 1- glycoprotein
大体时间:Day 56

inflammation status

Day 56
Retinol binding protein
大体时间:Day 1

Vitamin A status

Day 1
Retinol binding protein
大体时间:Day 28

Vitamin A status

Day 28
Retinol binding protein
大体时间:Day 56

Vitamin A status

Day 56
Plasma zinc
大体时间:Day 1

Zinc status

Day 1
COVID-19 specific T cell response
大体时间:Day 28

QuantiFERON SARS-CoV-2 whole blood assay - detection of IFN-gamma

Day 28
COVID-19 specific T cell response
大体时间:Day 56

QuantiFERON SARS-CoV-2 whole blood assay - detection of IFN-gamma

Day 56
COVID-19 specific T cell response
大体时间:Day 28

ELISpot assay on isolated peripheral blood mononuclear cells

Day 28
COVID-19 specific T cell response
大体时间:Day 56

ELISpot assay on isolated peripheral blood mononuclear cells

Day 56
Typhim Vi specific B-cell response
大体时间:Day 28

ELISpot assay on isolated peripheral blood mononuclear cells

Day 28
Typhim Vi specific B-cell response
大体时间:Day 56

ELISpot assay on isolated peripheral blood mononuclear cells

Day 56

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2023年11月1日

初级完成 (实际的)

2024年7月31日

研究完成 (实际的)

2024年7月31日

研究注册日期

首次提交

2023年10月30日

首先提交符合 QC 标准的

2023年10月30日

首次发布 (实际的)

2023年11月3日

研究记录更新

最后更新发布 (实际的)

2026年11月19日

上次提交的符合 QC 标准的更新

2026年11月16日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅